ArticleFrontiers in medicine2022

Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry.

Antonio Vitale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.